Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Alfresa Holdings Corporation (2784:JPX), powered by AI.
Alfresa Holdings Corporation is currently trading at ¥2,200. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Alfresa Holdings Corporation on Alpha Lenz.
Alfresa Holdings Corporation's P/E ratio is 14.9.
“Alfresa Holdings Corporation trades at a P/E of 14.9 (undervalued) with modest ROE of 5.7%.”
Ask for details →Alfresa Holdings Corporation is a prominent player in the Japanese healthcare and pharmaceutical distribution industry. Established in 2003 and headquartered in Tokyo, Alfresa Holdings is involved in the wholesale distribution of pharmaceuticals, diagnostic reagents, and medical devices. The company's primary function is to facilitate the reliable and efficient delivery of healthcare products from manufacturers to healthcare facilities, pharmacies, and consumers across Japan. Alfresa operates through a network of subsidiaries and associates, ensuring a wide-reaching and robust supply chain that supports the daily operations of the healthcare sector. Additionally, the company is actively engaged in promoting the development of healthcare solutions aimed at improving patient care and healthcare management. In the financial markets, Alfresa Holdings Corporation is recognized for its significant contributions to the healthcare supply chain, impacting sectors such as pharmaceuticals, biotechnology, and medical technology. This role underscores its importance in ensuring that essential medicines and medical supplies are readily available, thus supporting the health and wellbeing of communities throughout Japan.
“Alfresa Holdings Corporation trades at a P/E of 14.9 (undervalued) with modest ROE of 5.7%.”
Ask for details →Alfresa Holdings Corporation (ticker: 2784) is a company listed on JPX in the Healthcare sector (Medical Distribution). It has approximately 12,452 employees. Market cap is $409.4B.
The current price is 2,200 with a P/E ratio of 14.95x and P/B of 0.85x.
ROE is 5.70% and operating margin is 1.29%. Annual revenue is $3.0T.